Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder

Jie Lin, Binbin Xue, Jia Li, Ruofan Zhu, Juyuan Pan, Zhibo Chen, Xu Zhang, Xiang Li, Junhui XiaFrontiers in Neurology 2022 · DOI

TL;DR

This retrospective study compares two common immunosuppressive treatments—Rituximab (RTX) and Mycophenolate Mofetil (MMF)—for Chinese patients with Neuromyelitis Optica Spectrum Disorder (NMOSD). The results indicate that while both drugs are effective and tolerable for long-term use, low-dose RTX is significantly superior to MMF in reducing the annual relapse rate and extending the time between relapses.

What Problem Does This Paper Address?

Neuromyelitis Optica Spectrum Disorder (NMOSD) is a rare, debilitating autoimmune disease where the body’s immune system attacks the central nervous system, specifically targeting water channel proteins called aquaporin-4 (AQP4). This leads to severe inflammation of the optic nerves and spinal cord, often resulting in blindness or paralysis.

Because the disease follows a "relapse-remission" cycle—where each new attack causes cumulative, irreversible neurological damage—preventing relapses is the primary goal of treatment. While Rituximab (a B-cell depleting monoclonal antibody) and Mycophenolate Mofetil (an immunosuppressant) are widely used, there is a lack of long-term comparative data on their efficacy, particularly regarding "low-dose" RTX regimens. These lower doses are of high interest in regions like China, where the high cost of standard-dose biologics can be a barrier to treatment.

Methods

The researchers conducted a retrospective review of 39 patients at the First Affiliated Hospital of Wenzhou Medical University treated between 2013 and 2020.

  • The RTX Group (18 patients): Received a "low-dose" induction of 375 mg/m² once. Crucially, instead of a fixed schedule, re-treatment was only administered when the patient's CD19+ B-cell count exceeded 1% of total lymphocytes.
  • The MMF Group (21 patients): Received a standard oral dose of 500 mg twice daily.
  • Evaluation Metrics: The primary endpoints were the Annual Relapse Rate (ARR) and the Expanded Disability Status Scale (EDSS) score. They also used Kaplan-Meier analysis to estimate the "time to next relapse" and a COX proportional hazards model to calculate the relative risk of relapse between the two groups.

Datasets

The study utilized a localized clinical dataset of 39 Chinese patients diagnosed with NMOSD based on the 2015 revised international criteria.

  • RTX Group: Median follow-up of 52 months.
  • MMF Group: Median follow-up of 30 months.
  • Serology: Most patients (17 in RTX, 18 in MMF) were positive for AQP4 antibodies.

Key Insights and Ideas

  • Tailored Dosing Works: The study demonstrates that a B-cell-triggered "low-dose" RTX regimen is highly effective. By monitoring CD19+ B-cells and only dosing when they repopulate, clinicians can maintain disease stability while potentially reducing costs and long-term side effects.
  • RTX Superiority in Relapse Prevention: While both drugs worked, the "aha moment" was the magnitude of difference. Patients on RTX had a significantly longer duration of first relapse-free survival compared to those on MMF.
  • Disability Reversal: Interestingly, both treatments didn't just stop the disease from getting worse; they actually led to a reduction in EDSS scores, meaning patients' neurological function improved over the long-term follow-up period.
  • Safety Profile: Both drugs were found to be "tolerable." The most common adverse events were infections (respiratory and urinary), which were generally mild to moderate.

Key Results

  • Relapse Reduction: In the RTX group, the mean ARR dropped from 2.83 before treatment to just 0.13 after. In the MMF group, it dropped from 1.29 to 0.26.
  • Disability Improvement: RTX showed a better reduction in EDSS scores (a change of 1.31) compared to MMF (a change of 0.55).
  • Hazard Ratio (HR): The COX model showed an HR of 0.179 for the RTX group. This means that, after adjusting for variables like age and disease duration, patients on RTX had roughly an 82% lower risk of relapse compared to those on MMF.
  • Relapse-Free Survival: Kaplan-Meier curves showed a clear, statistically significant advantage for RTX in keeping patients relapse-free over time (p = 0.010).

Limitations and Future Work

The authors acknowledge several limitations:

  1. Retrospective Design: As a review of past records, the study may have inherent selection biases.
  2. Small Sample Size: With only 39 patients, the statistical power is limited, particularly for detecting rare adverse events.
  3. Washout Period: The study did not account for a "washout period" to eliminate the influence of treatments patients may have been on before the study began.
  4. Testing Gaps: Dynamic testing of AQP4-antibody levels was not available for all patients throughout the study.

The authors conclude that while low-dose RTX is a superior preventive strategy for NMOSD in this population, a larger, randomized prospective trial is needed to confirm these findings.

Summary updated

Abstract

Long-term using of low dose of RTX and MMF were effective and tolerable in Chinese patients with NMOSD. Compared with MMF, RTX showed a better way to reduce the ARR.
BibTeX
@inproceedings{lin2022comparison,
  author = {Jie Lin and Binbin Xue and Jia Li and Ruofan Zhu and Juyuan Pan and Zhibo Chen and Xu Zhang and Xiang Li and Junhui Xia},
  title = {{Comparison of Long-Term Use of Low Dose Rituximab and Mycophenolate Mofetil in Chinese Patients With Neuromyelitis Optica Spectrum Disorder}},
  booktitle = {Frontiers in Neurology},
  year = {2022},
  doi = {10.3389/fneur.2022.891064},
}
Figure